Immunobullous Diseases Flashcards

1
Q

Pemphigus Foliaceus: Target Protein

A

Desmoglein 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pemphigus Vulgaris: Target Protein

A

Desmoglein 3, +/-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Bullous pemphigoid: Target Protein

A

HEMIDESMOSOME BPAG2 = BP180, BPAG1 = BP230

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pemphigus foliaceus: clinical presentation

A

Superficial crusted erosions, +/- itch Distribution: face, scalp, upper central chest/back, proximal arms/legs NEVER affects mucosa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pemphigus foliaceus: key word

A

“Cornflake crust”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pemphigus foliaceus: DDx

A

Psoriasis, Eczema, Seborrheic dermatitis/scalp psoriasis, bullous impetigo (S. aureus), staphylococcal scalded skin syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pemphigus vulgaris: clinical presentation

A

MUCOSAL EROSIONS: 1. oropharyngeal, vaginal, esophageal, nasal, conjuctiva 2. NOT oral ulcers MUCOCUTEANOUS PV: widespread deep erosions 1. mucosa, face, scalp, trunk, extremities 2. spares palms and soles 3. can be itchy or painful

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pemphigus vulgaris: DDx

A

Mucosal PV: 1. HSV, Lichen planus, erythema multiforme Mucocutaneous: 1. SJS, disseminated zoster, TEN, erythema multiforme, paraneoplastic pemphigus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Important sign in PV?

A

Nikolsky sign: blister will extend or be induced when lateral pressure is applied

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bullous pemphigoid: clinical presentation

A

Tense bullae (arms, leg, trunk) Less often: face/scalp, mucosal, palms/soles INTENSELY ITCHY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

BP variants?

A
  1. urticarial variant 2. localized (pretibial, around stomas, post-surgical)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

BP: DDx

A
  1. Acute allergic contact dermatitis 2. Urticaria / urticarial drug reaction 3. Subepidermal immunobullous 4. Subepidermal non-immunobullous
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How to Dx immunobullous diseases?

A
  1. Skin biopsy for histology 2. Immunofluorescence studies 3. Enzyme-linked immunosorbent assay
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

PV histology

A

Acantholysis, cytolysis, “ROW OF TOMBSTONES” – hemidesmosomes intact, desmosomes connecting keratinocytes to each other are damaged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

PF histology

A

Superficial acantholysis, eosinophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Desmoglein compensation theory

A

Different isoforms can compensate for one another in regard to their adhesive function in the epidermis

17
Q

Normal human skin: Dsg1 distribution

A

High in epidermis, low in dermis - normal skin High in epidermis, absent in dermis - mucous membranes

18
Q

Normal human skin: Dsg3 distribution

A

High in dermis, low in epidermis - normal skin Constant throughout mucous membranes

19
Q

PF blisters: where are they?

A

Superficial epidermis (no Dsg3 compensation) -never in mucous membranes

20
Q

Mucosal PV blisters: where are they?

A

Suprabasal blisters in mucous membranes - tombstoning

21
Q

Mucucutaneous PV blisters: where are they?

A

anti-Dsg1 and anti-Dsg3 antibodies Suprabasal blisters in mucous membranes - tombstoning Suprabasal blisters due to inactivation of Dsgs throughout the skin

22
Q

Are antibodies causative?

A

Seems to be the case, yes

23
Q

Mechanisms of acantholysis

A

1.Steric hindrance 2. Induction of cellular signaling pathways (e.g. pathogenic antibodies that cause endocytosis of cell surface Dsgs, regulated by p38 MAPK)

24
Q

Double-edged sword for immunity?

A

Anti-Dsg1 antibodies are protective for Leishmania infection

25
Bullous pemphigoid: pathophys
Anti-BP antibody binds target protein, initiates complement activation + inflammation --\> release of proteolytic enzymes --\> tissue damage
26
Difference from staphylococcal-mediated blistering?
IF negative (b/c not immune-mediated, toxin directly cleaves Dsg1)
27
Therapy
1. Treat early 2. Steroids + immunosuppressants 3. Anti-staph antibiotics help PF 4. Remissions can occur
28
Prognosis
\>90% survival, but patients can die from complications of therapy
29
Pemphigus foliaceus
30
Pemphigus vulgaris
31
Mucosal pemphigus vulgaris
32
Bullous pemphigus